BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 18619571)

  • 1. Intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
    Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Arevalo JF; Ziemssen F; Mehio-Sibai A; Mackensen F; Adan A; Chan WM; Ness T; Banker AS; Dodwell D; Chau Tran TH; Fardeau C; Lehoang P; Mahendradas P; Berrocal M; Tabbarah Z; Hrisomalos N; Hrisomalos F; Al-Salem K; Guthoff R
    Am J Ophthalmol; 2009 Aug; 148(2):310-316.e2. PubMed ID: 19427992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
    Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
    Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
    Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
    Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
    Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.
    Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Ares S; Lopez-Lopez F; Rodriguez M; Fernandez M
    Eye (Lond); 2009 Feb; 23(2):334-8. PubMed ID: 18064056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.
    Yamamoto I; Rogers AH; Reichel E; Yates PA; Duker JS
    Br J Ophthalmol; 2007 Feb; 91(2):157-60. PubMed ID: 16870653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.